Nathan Bush

Nathan Bush

DLA Piper

Contact
View Bio
RSS

Latest Posts › Pharmaceutical Industry

Share:

The Future of "Counterparty Bribery" Offenses Under China's Anti-Unfair Competition Law

Pending proposals to amend China's Anti-Unfair Competition Law (AUCL) may further blur the line between antitrust and anti-corruption offenses under China's enigmatic "counterparty bribery" rules. The AUCL, first enacted in...more

3/31/2025  /  Anti-Corruption , Antitrust Provisions , Bribery , China , Enforcement Actions , Pharmaceutical Industry , Proposed Amendments , Proposed Legislation , Regulatory Requirements , Unfair Competition
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide